Kenía - enska - Pharmacy and Poisons Board

dawa limited p.o. box 16633-00620, nairobi,kenya - paracetamol - effervescent tablet - each uncoated effervescent tablet contains:… - paracetamol

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - potassium clavulanate; amoxicillin trihydrate; amoxycillin trihydrate -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - potassium clavulanate; amoxicillin trihydrate; amoxycilin trihydrate -

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin sodium 1.06 g equivalent to amoxicillin 1 g - as part of a 5:1 mix;  ; potassium clavulanate 238.3mg equivalent to clavulanic acid 200 mg - as part of a 5:1 mix - powder for injection - 1000/200mg - active: amoxicillin sodium 1.06 g equivalent to amoxicillin 1 g - as part of a 5:1 mix   potassium clavulanate 238.3mg equivalent to clavulanic acid 200 mg - as part of a 5:1 mix - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media; lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia; genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections; skin and soft tissue infections; bone and joint infections: e.g. osteomyelitis; other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxicillin susceptible organisms are amenable to amoxicillin/clavulanic acid treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organisms in conjunction with amoxicillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxicillin/clavulanic acid.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin sodium 530.1mg equivalent to amoxicillin 500 mg as part of a 5:1 mix;  ; potassium clavulanate 119.2mg equivalent to clavulanic acid 100 mg - as part of a 5:1 mix - powder for injection - 500/100mg - active: amoxicillin sodium 530.1mg equivalent to amoxicillin 500 mg as part of a 5:1 mix   potassium clavulanate 119.2mg equivalent to clavulanic acid 100 mg - as part of a 5:1 mix - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media; lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia; genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections; skin and soft tissue infections; bone and joint infections: e.g. osteomyelitis; other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxicillin susceptible organisms are amenable to amoxicillin/clavulanic acid treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organisms in conjunction with amoxicillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxicillin/clavulanic acid.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin sodium 2.12 g equivalent to amoxicillin 2 g - as part of a 10:1 mix;  ; potassium clavulanate 238.3mg equivalent to clavulanic acid 200 mg - as part of a 10:1 mix - powder for injection - active: amoxicillin sodium 2.12 g equivalent to amoxicillin 2 g - as part of a 10:1 mix   potassium clavulanate 238.3mg equivalent to clavulanic acid 200 mg - as part of a 10:1 mix - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media; lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia; genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections; skin and soft tissue infections; bone and joint infections: e.g. osteomyelitis; other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxicillin susceptible organisms are amenable to amoxicillin/clavulanic acid treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organisms in conjunction with amoxicillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxicillin/clavulanic acid.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxycillin trihydrate; potassium clavulanate -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - potassium clavulanate; amoxycillin trihydrate -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate,potassium clavulanate -

Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - amoxycillin trihydrate; potassium clavulanate -